HEALTHglobal
Aspen’s fresh Parkinson’s data; Aldeyra tanks following FDA rejection
Single source
Updated 2 hours ago
First seen March 18, 2026 17:11:22Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Aspen Neuroscience presented positive Phase 1/2 data for its stem cell-derived therapy. Elsewhere, Aldeyra lost over half its market value following a rejection from the FDA.